Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
122 hedge funds and large institutions have $119M invested in Evofem Biosciences, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 37 increasing their positions, 5 reducing their positions, and 5 closing their positions.
1,420% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 5
640% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 5
139% more funds holding
Funds holding: 51 → 122 (+71)
61% more call options, than puts
Call options by funds: $1.3M | Put options by funds: $809K
39% less capital invested
Capital invested by funds: $195M → $119M (-$76.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$13.7M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$10.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.62M |
| 4 |
Millennium Management
New York
|
+$7.99M |
| 5 |
HP
Hound Partners
New York
|
+$4.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$23M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$2.39M |
| 3 |
TWMP
Taylor Wealth Management Partners
Boston,
Massachusetts
|
-$138K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$108K |
| 5 |
DC
Davenport & Co
Richmond,
Virginia
|
-$84.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Simplex Trading
Chicago,
Illinois
| – | +$105K | +1,552 | New |
|
EVFM Hedge Fund Activity: Q2 2020 in Review
122 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q2 2020, worth a combined $119M — down 39% from $195M a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new EVFM positions and 5 closed out — a net gain of 71 holders — while 37 added to existing stakes and 5 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $13.7M. The largest seller was BlackRock, cutting an estimated $23M.
- 122 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q2 2020, up from 51 in Q1 2020.
- Funds reported $119M of Evofem Biosciences, Inc. Common Stock stock for Q2 2020, down 39% quarter-over-quarter.
- 76 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q2 2020 and 5 closed out, a net change of +71 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q2 2020 was Morgan Stanley, an estimated $13.7M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q2 2020 was BlackRock, an estimated $23M sold.
Based on aggregated 13F filings for Q2 2020.